Ginkgo supplement suppresses steroid-induced ocular hypertension

Article

Gingko biloba extract (GBE) has an application in preventing steroid-induced ocular hypertension, according to study results published in the December issue of the Archives of Ophthalmology.

Gingko biloba extract (GBE) has an application in preventing steroid-induced ocular hypertension, according to study results published in the December issue of the Archives of Ophthalmology.

Li-Yun Jia, PhD of the Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Hong Kong and colleagues treated rabbits four times daily with topical TobraDEX (Alcon) and/or GBE 5 µg for 14 days. Intraocular pressure (IOP) was measured at three day intervals; the trabecular meshwork and extracellular matrix were enucleated, and cellularity and deposition graded.

GBE suppressed IOP increases caused by steroid application, and improved the cellularity of the trabecular meshwork. Applying GBE to cultured human trabecular meshwork cells inhibited the effects of the steroid: GBE attenuated apoptosis induced by anti-Fas ligands, reduced expression of myocilin and modulated the expression of stress-related genes heat-shock proteins 70 and 90, as well as the expression of B-crystallin.

As GBE proved a safe and effective means of preventing steroid-induced ocular hypertension in both an animal model and in human cells in vivo, the researchers concluded that this herbal compound could potentially be used as a dietary supplement used to prevent this type of hypertension.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.